In individuals with type 2 diabetes and high cardiovascular risk, current consensus recommends treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular disease benefit and low risk of hypoglycemia (5). Here, SLC5A2 is linked to type 2 diabetes mellitus.